drugset / Trial / NCT05477498
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction
Phase 4
Withdrawn
Cantonal Hosptal, Baselland
Clinical Trial Unit, University Hospital Basel, Switzerland · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to investigate the effects of treatment with intravenous ferric carboxymaltose on exercise tolerance measured as VO2peak in patients with HFpEF and iron deficiency, compared to placebo.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-08-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 500 mg | Intravenous |
| Subject | Ferric carboxymaltose | Other / unclassified | 1000 mg | Intravenous |